CEO David DeStefano highlighted Vertex's strong start to 2025, reporting $177.1 million in revenue, a 12.9% year-over-year increase, supported by 14.4% growth in subscription revenue and 29.6% growth ...
BMO Capital Markets analyst Daniel Jester reiterated the Market Perform rating on Vertex, Inc. (NASDAQ:VERX), raising the price target to $28 from $24. Investors rewarded the consistent execution ...
Vertex Pharmaceuticals stock was heading for a double-digit gain this year until recent weeks. The company is approaching an important turning point -- one that could set the tone for revenue growth.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback